View Older Stories View More Recent Stories

Apr 28, 2026 08:30AM PolyPid to present surgical infection data at medical conference
Apr 28, 2026 08:30AM PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Apr 13, 2026 09:15AM PolyPid to present D-PLEX100 trial data at ESCMID Global 2026
Apr 13, 2026 09:15AM PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Mar 31, 2026 08:30AM PolyPid begins FDA submission for surgical infection drug
Mar 31, 2026 08:30AM PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
Mar 17, 2026 08:30AM PolyPid receives $4.3 million FDA fee waiver for drug application
Mar 17, 2026 08:30AM PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
Feb 25, 2026 08:35AM PolyPid Announces Participation in Upcoming Investor Conferences
Feb 11, 2026 07:31AM PolyPid advances D-PLEX100 partnership talks, plans NDA filing
Feb 11, 2026 07:30AM PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Jan 28, 2026 08:00AM PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
Dec 16, 2025 08:30AM PolyPid names Brooke Story as board chairman
Dec 16, 2025 08:30AM PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Dec 3, 2025 08:32AM PolyPid receives FDA support for D-PLEX100 drug application submission
Dec 3, 2025 08:30AM PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
Nov 25, 2025 08:30AM PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
Nov 12, 2025 07:30AM PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Nov 6, 2025 08:30AM PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
Nov 6, 2025 08:30AM PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
Oct 29, 2025 08:30AM PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
Sep 30, 2025 08:45AM PolyPid to present phase 3 SHIELD II trial results at surgical conference
Sep 30, 2025 08:45AM PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
Sep 17, 2025 08:44AM PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
Sep 16, 2025 08:33AM PolyPid completes israeli health ministry GMP inspection
Sep 16, 2025 08:30AM PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
Sep 3, 2025 08:30AM PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Sep 2, 2025 08:30AM PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
Aug 13, 2025 07:30AM PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Aug 12, 2025 08:00AM PolyPid names Dr. Nurit Tweezer-Zaks as chief medical officer
Aug 12, 2025 08:00AM PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Jul 30, 2025 08:00AM PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
Jul 15, 2025 08:00AM PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment
Jul 15, 2025 08:00AM PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
Jun 16, 2025 07:20PM PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
Jun 9, 2025 07:32AM PolyPid Ltd. (PYPD) to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Jun 6, 2025 04:05PM PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
May 20, 2025 07:00AM PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
May 14, 2025 07:00AM PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
Apr 29, 2025 07:00AM PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
Apr 22, 2025 07:00AM PolyPid to Participate in The Citizens Life Sciences Conference
Mar 3, 2025 07:00AM PolyPid to Participate in the 37th Annual ROTH Conference
Feb 12, 2025 07:00AM PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Jan 30, 2025 07:00AM PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 29, 2025 07:00AM PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
Dec 23, 2024 07:22PM PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
Dec 11, 2024 07:02AM PolyPid Ltd. (PYPD) Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Dec 11, 2024 07:00AM PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Nov 29, 2024 01:06PM PolyPid Ltd. (PYPD) Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
Nov 29, 2024 01:05PM PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
View More Recent Stories View Older Stories